The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict MAKO Surgical's revenues will increase 20.5% and EPS will remain in the red.
The average estimate for revenue is $28.5 million. On the bottom line, the average EPS estimate is -$0.20.
Last quarter, MAKO Surgical logged revenue of $24.8 million. GAAP reported sales were 26% higher than the prior-year quarter's $19.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.21. GAAP EPS were -$0.21 for Q1 versus -$0.28 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 73.6%, 150 basis points better than the prior-year quarter. Operating margin was -36.0%, much better than the prior-year quarter. Net margin was -38.8%, much better than the prior-year quarter.
The full year's average estimate for revenue is $126.1 million. The average EPS estimate is -$0.59.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,222 members out of 1,269 rating the stock outperform, and 47 members rating it underperform. Among 318 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 307 give MAKO Surgical a green thumbs-up, and 11 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MAKO Surgical is outperform, with an average price target of $14.57.
Is MAKO Surgical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add MAKO Surgical to My Watchlist.